david@lifesciadvisors.com

Home/David Sherman

About David Sherman

This author has not yet filled in any details.
So far David Sherman has created 306 blog entries.

Paratek Pharmaceuticals, Inc. Reports Second Quarter 2017 Financial Results and Provides Clinical Update

BOSTON, Aug. 02, 2017 (GLOBE NEWSWIRE) — Paratek Pharmaceuticals, Inc. (PRTK), a biopharmaceutical company focused on the development and commercialization of innovative therapies based upon tetracycline chemistry, today reported financial results and provided an update on financial, clinical and regulatory filing activities for the quarter ended June 30, 2017.

By | 2017-08-02T11:41:28+00:00 August 2nd, 2017|Lifesci News|Comments Off on Paratek Pharmaceuticals, Inc. Reports Second Quarter 2017 Financial Results and Provides Clinical Update

Frost & Sullivan Lauds CytoSorbents for Leading the Critical Care Immunotherapy Segment with its Novel Blood Purification Solution, CytoSorb®

LONDON, Aug. 2, 2017 /PRNewswire/ — Based on its recent analysis of the blood purification market, Frost & Sullivan recognizes CytoSorbents Corporation with the 2017 Global Frost & Sullivan Award for Product Leadership. CytoSorbents’ deceptively simple yet powerful blood purification therapy, CytoSorb®, helps critical care physicians and heart surgeons control deadly inflammation in their […]

By | 2017-08-02T11:40:09+00:00 August 2nd, 2017|Lifesci News|Comments Off on Frost & Sullivan Lauds CytoSorbents for Leading the Critical Care Immunotherapy Segment with its Novel Blood Purification Solution, CytoSorb®

Sierra Oncology to Present at the 2017 Wedbush PacGrow Healthcare Conference

VANCOUVER, Aug. 2, 2017 /PRNewswire/ – Sierra Oncology, Inc. (SRRA), a clinical stage drug development company focused on advancing next generation DNA Damage Response (DDR) therapeutics for the treatment of patients with cancer, today announced that Dr. Nick Glover, President and Chief Executive Officer, will present an overview of the company […]

By | 2017-08-02T11:38:41+00:00 August 2nd, 2017|Lifesci News|Comments Off on Sierra Oncology to Present at the 2017 Wedbush PacGrow Healthcare Conference

VBL Therapeutics to Report Second Quarter 2017 Results on August 14

TEL AVIV, Israel, Aug. 02, 2017 (GLOBE NEWSWIRE) — VBL Therapeutics (VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class treatments for cancer, today announced that it will host a conference call and live audio webcast on Monday, August 14, 2017 at 8:30am Eastern Time to report second quarter […]

By | 2017-08-02T11:36:40+00:00 August 2nd, 2017|Lifesci News|Comments Off on VBL Therapeutics to Report Second Quarter 2017 Results on August 14

Lipocine to Present at the Canaccord Genuity 37th Annual Growth Conference

SALT LAKE CITY, Aug. 02, 2017 (GLOBE NEWSWIRE) — Lipocine Inc. (LPCN), a specialty pharmaceutical company, announced today that Dr. Mahesh Patel, Chairman, President and CEO, will provide a corporate overview at the Canaccord Genuity 37th Annual Growth Conference, being held August 9-10, 2017 at the InterContinental Boston Hotel in […]

By | 2017-08-02T11:35:14+00:00 August 2nd, 2017|Lifesci News|Comments Off on Lipocine to Present at the Canaccord Genuity 37th Annual Growth Conference

AgeX Therapeutics Obtains $10 Million in Capital and Commences Operations

ALAMEDA, Calif.– (BUSINESS WIRE) — AgeX Therapeutics, Inc. (AgeX), a subsidiary of BioTime, Inc. (NYSE MKT: BTX), today reported that it has successfully raised $10 million in equity financing to fund its operations. Following the financing, BioTime continues to own about 87% of AgeX’s outstanding shares. The financing is expected to […]

By | 2017-08-02T11:34:08+00:00 August 2nd, 2017|Lifesci News|Comments Off on AgeX Therapeutics Obtains $10 Million in Capital and Commences Operations

Advaxis to Present at Third CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference: Translating Science into Survival

PRINCETON, N.J. — (BUSINESS WIRE) — Advaxis, Inc. (ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, today announced three abstracts were selected for presentation at the third annual CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference: Translating Science […]

By | 2017-08-02T11:32:48+00:00 August 2nd, 2017|Lifesci News|Comments Off on Advaxis to Present at Third CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference: Translating Science into Survival

VALNEVA Announces Expansion of its Management Board – Strengthening Senior Management for Future Growth

Lyon (France), August 1, 2017 – Valneva SE (“Valneva” or “the Company”), a fully integrated commercial stage biotech company focused on developing innovative, lifesaving vaccines, is pleased to announce the expansion of its Management Board with two new appointments: David Lawrence as Chief Financial Officer (CFO) and Wolfgang Bender, MD, PhD as Chief Medical Officer […]

By | 2017-08-01T18:47:06+00:00 August 1st, 2017|Lifesci News|Comments Off on VALNEVA Announces Expansion of its Management Board – Strengthening Senior Management for Future Growth

Vermillion to Present at the Canaccord Genuity 37th Annual Growth Conference on August 10th

AUSTIN, Texas, Aug. 1, 2017 /PRNewswire/ — Vermillion, Inc. (VRML), a bio-analytical solutions company focused on gynecologic disease, today announced that Valerie Palmieri, President and Chief Executive Officer, will provide a corporate overview at the Canaccord Genuity 37th Annual Growth Conference, being held August 9-10 in Boston, Massachusetts.

By | 2017-08-01T18:45:42+00:00 August 1st, 2017|Lifesci News|Comments Off on Vermillion to Present at the Canaccord Genuity 37th Annual Growth Conference on August 10th

Ocera Therapeutics Reports Second Quarter 2017 Financial Results

REDWOOD CITY, Calif. and RESEARCH TRIANGLE PARK, N.C., Aug. 01, 2017 (GLOBE NEWSWIRE) — Ocera Therapeutics, Inc. (OCRX), a clinical stage biopharmaceutical company focused on the development of OCR-002 for the treatment and prevention of hepatic encephalopathy (HE), a debilitating complication of liver disease and significant burden on the healthcare system, today reported financial […]

By | 2017-08-01T18:44:36+00:00 August 1st, 2017|Lifesci News|Comments Off on Ocera Therapeutics Reports Second Quarter 2017 Financial Results

TRACON to Report Second Quarter Company Highlights and Financial Results on August 8, 2017

SAN DIEGO, Aug. 01, 2017 (GLOBE NEWSWIRE) — TRACON Pharmaceuticals (TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer, wet age-related macular degeneration and fibrotic diseases, announced today that it will report its second quarter financial and operating results after the close of U.S. financial […]

By | 2017-08-01T18:43:26+00:00 August 1st, 2017|Lifesci News|Comments Off on TRACON to Report Second Quarter Company Highlights and Financial Results on August 8, 2017

Prothena to Report Second Quarter 2017 Financial Results on August 8

DUBLIN, Ireland, Aug. 01, 2017 (GLOBE NEWSWIRE) — Prothena Corporation plc (PRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel protein immunotherapies, will announce financial results for the second quarter and first six months of 2017 on August 8, 2017 after the close of the U.S. financial markets.

By | 2017-08-01T18:42:19+00:00 August 1st, 2017|Lifesci News|Comments Off on Prothena to Report Second Quarter 2017 Financial Results on August 8

DURECT Corporation Invites You to Join its Second Quarter 2017 Earnings Conference Call

CUPERTINO, Calif., Aug. 1, 2017 /PRNewswire/ — In conjunction with DURECT Corporation’s (DRRX) second quarter 2017 financial results press release, you are invited to listen to a conference call that will be broadcast live over the internet on Tuesday, August 8, 2017 at 4:30 pm Eastern Time (1:30 pm Pacific […]

By | 2017-08-01T18:41:05+00:00 August 1st, 2017|Lifesci News|Comments Off on DURECT Corporation Invites You to Join its Second Quarter 2017 Earnings Conference Call

Gemphire Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

LIVONIA, Mich., Aug. 01, 2017 (GLOBE NEWSWIRE) — Gemphire Therapeutics Inc. (GEMP), today announced that on July 31, 2017, the Compensation Committee of its Board of Directors, which is composed entirely of independent directors, approved an equity award under Gemphire’s Inducement Plan, as a material inducement to one individual entering into employment with Gemphire.  […]

By | 2017-08-01T18:39:57+00:00 August 1st, 2017|Lifesci News|Comments Off on Gemphire Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

Zealand Pharma A/S commences initial public offering of American Depositary Shares in the United States

Copenhagen, August 1, 2017 – With reference to the company announcement no. 25/2017, dated July 6, 2017, regarding the initial public filing of registration statement on Form F-1 (the “F-1”) with the U.S. Securities and Exchange Commission (the “SEC”) for a proposed initial public offering of American Depositary Shares (“ADSs”) on The Nasdaq Global Select […]

By | 2017-08-01T18:38:39+00:00 August 1st, 2017|Lifesci News|Comments Off on Zealand Pharma A/S commences initial public offering of American Depositary Shares in the United States

Kamada Reports Financial Results for Second Quarter and First Six Months of 2017

REHOVOT, Israel, Aug. 01, 2017 (GLOBE NEWSWIRE) — Kamada Ltd. (KMDA) (KMDA), a plasma-derived protein therapeutics company focused on orphan indications, today announced financial results for the three and six months ended June 30, 2017.

By | 2017-08-01T14:32:56+00:00 August 1st, 2017|Lifesci News|Comments Off on Kamada Reports Financial Results for Second Quarter and First Six Months of 2017

CytoSorbents to Report Q2 2017 Operating and Financial Results

MONMOUTH JUNCTION, N.J., Aug. 1, 2017 /PRNewswire/ — CytoSorbents Corporation (CTSO),  CytoSorbents Corporation (CTSO), a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, will report Q2 2017 financial results after the market close on

By | 2017-08-01T14:31:37+00:00 August 1st, 2017|Lifesci News|Comments Off on CytoSorbents to Report Q2 2017 Operating and Financial Results

Mateon Therapeutics Completes Enrollment in Phase 2 Portion of FOCUS Study of CA4P for Platinum-Resistant Ovarian Cancer

SOUTH SAN FRANCISCO, Calif., Aug. 01, 2017 (GLOBE NEWSWIRE) — Mateon Therapeutics, Inc. (MATN), a biopharmaceutical company developing vascular disrupting agents (VDAs) for the treatment of orphan oncology indications, today announced that it has completed enrollment of more than 80 patients in the phase 2 portion of its FOCUS study evaluating CA4P in combination […]

By | 2017-08-01T14:30:16+00:00 August 1st, 2017|Lifesci News|Comments Off on Mateon Therapeutics Completes Enrollment in Phase 2 Portion of FOCUS Study of CA4P for Platinum-Resistant Ovarian Cancer

iCAD to Present at the Canaccord Genuity 37th Annual Growth Conference

NASHUA, N.H., Aug. 01, 2017 (GLOBE NEWSWIRE) — iCAD, Inc. (ICAD), an industry-leading provider of advanced image analysis, workflow solutions and radiation therapy for the early identification and treatment of cancer, today announced that management will be providing a corporate update at the Canaccord Genuity 37th Annual Growth Conference, being held August 9-10 in […]

By | 2017-08-01T14:29:03+00:00 August 1st, 2017|Lifesci News|Comments Off on iCAD to Present at the Canaccord Genuity 37th Annual Growth Conference

Zogenix to Release Second Quarter 2017 Financial Results and Host Conference Call and Webcast on August 8

EMERYVILLE, Calif., Aug. 01, 2017 (GLOBE NEWSWIRE) — Zogenix, Inc. (ZGNX), a pharmaceutical company developing therapies for the treatment of orphan and central nervous system (CNS) disorders, today announced that it will report its financial results for the second quarter ended June 30, 2017, after the market close, and will host a corporate update […]

By | 2017-08-01T14:27:55+00:00 August 1st, 2017|Lifesci News|Comments Off on Zogenix to Release Second Quarter 2017 Financial Results and Host Conference Call and Webcast on August 8

Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

BOSTON, Aug. 01, 2017 (GLOBE NEWSWIRE) — Paratek Pharmaceuticals, Inc. (PRTK), a biopharmaceutical company focused on the development and commercialization of innovative therapies based upon tetracycline chemistry, today announced that on July 31, 2017, the Company granted stock options and restricted stock units to four new employees of the Company. These awards were granted […]

By | 2017-08-01T14:26:49+00:00 August 1st, 2017|Lifesci News|Comments Off on Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Threshold Pharmaceuticals Announces Results of Annual Meeting of Stockholders

MENLO PARK, Calif., Aug. 01, 2017 (GLOBE NEWSWIRE) — Threshold Pharmaceuticals, Inc. (THLD) announced today that its stockholders approved all of the proposals presented at the Annual Meeting of Stockholders held on July 31, 2017, including all proposals related to the merger with Molecular Templates, Inc.  As a result of the stockholder approvals, on […]

By | 2017-08-01T14:25:37+00:00 August 1st, 2017|Lifesci News|Comments Off on Threshold Pharmaceuticals Announces Results of Annual Meeting of Stockholders

Reata Pharmaceuticals, Inc. Announces Closing of Class A Common Stock Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

IRVING, Texas, Aug. 01, 2017 (GLOBE NEWSWIRE) — Reata Pharmaceuticals, Inc. (RETA) (“Reata” or the “Company”), a clinical-stage biopharmaceutical company, today announced the closing of its previously announced underwritten public offering of 3,737,500 shares of its Class A common stock, which included 487,500 shares sold pursuant to the underwriters’ full exercise of their option […]

By | 2017-08-01T14:24:19+00:00 August 1st, 2017|Lifesci News|Comments Off on Reata Pharmaceuticals, Inc. Announces Closing of Class A Common Stock Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

VALNEVA Announces Expansion of its Management Board – Strengthening Senior Management for Future Growth

Lyon (France), August 1, 2017 – Valneva SE (“Valneva” or “the Company”), a fully integrated commercial stage biotech company focused on developing innovative, lifesaving vaccines, is pleased to announce the expansion of its Management Board with two new appointments: David Lawrence as Chief Financial Officer (CFO) and Wolfgang Bender, MD, PhD as Chief Medical Officer […]

By | 2017-08-01T14:22:35+00:00 August 1st, 2017|Lifesci News|Comments Off on VALNEVA Announces Expansion of its Management Board – Strengthening Senior Management for Future Growth

Transgene: First Patient Dosed in a Phase 1/2 Trial of Pexa-Vec + Opdivo® for the First-Line Treatment of Advanced Liver Cancer

Transgene (TNG.PA), a company that designs and develops viral-based immunotherapies, today announces that the first patient has been treated in a Phase 1/2 clinical trial evaluating the combination of Pexa-Vec with Opdivo® (nivolumab) as a first-line treatment of advanced hepatocellular carcinoma (HCC), which accounts for approximately 75% of liver cancers. This open-label trial will assess […]

By | 2017-07-31T21:05:42+00:00 July 31st, 2017|Lifesci News|Comments Off on Transgene: First Patient Dosed in a Phase 1/2 Trial of Pexa-Vec + Opdivo® for the First-Line Treatment of Advanced Liver Cancer

Onxeo Divests Two Non-Core Products in Oral Pathologies to Vectans Pharma

Onxeo S.A. (ONXEO.PA) (NASDAQ OMX:ONXEO) (Euronext Paris, NASDAQ Copenhagen: ONXEO), (“Onxeo” or the “Company”), a clinical-stage biotechnology company specializing in the development of innovative drugs for the treatment of orphan diseases, in particular in oncology, today announced the sale of two historical products Sitavig® and Loramyc®1 to Vectans Pharma, a private pharmaceutical company which […]

By | 2017-07-31T21:04:17+00:00 July 31st, 2017|Lifesci News|Comments Off on Onxeo Divests Two Non-Core Products in Oral Pathologies to Vectans Pharma

Spring Bank Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2017 Financial and Operational Results

HOPKINTON, Mass., July 31, 2017 (GLOBE NEWSWIRE) — Spring Bank Pharmaceuticals, Inc. (SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, inflammatory diseases and certain cancers, today announced second quarter 2017 financial results and provided an update on recent corporate and clinical developments.

By | 2017-07-31T21:00:19+00:00 July 31st, 2017|Lifesci News|Comments Off on Spring Bank Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2017 Financial and Operational Results

Arena Pharmaceuticals to Release Second Quarter 2017 Financial Results and Provide Corporate Update on Monday, August 7, 2017

SAN DIEGO, July 31, 2017 /PRNewswire/ — Arena Pharmaceuticals, Inc. (ARNA), today announced that the Company will release its second quarter 2017 financial results and provide a corporate update on Monday, August 7, 2017, after the close of the U.S. financial markets.  The Company will host a […]

By | 2017-07-31T20:58:42+00:00 July 31st, 2017|Lifesci News|Comments Off on Arena Pharmaceuticals to Release Second Quarter 2017 Financial Results and Provide Corporate Update on Monday, August 7, 2017